You are here

Marburg Virus Prophylactic Medical Countermeasure

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911-QY-20-C-0057
Agency Tracking Number: C2-0538
Amount: $537,470.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: CBD18A-002
Solicitation Number: 18.A
Timeline
Solicitation Year: 2018
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-05-12
Award End Date (Contract End Date): 2022-05-11
Small Business Information
45 Quail Ct 300
Walnut Creek, CA 94596
United States
DUNS: 080129637
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Reid Rubsamen
 Founder, President & CEO
 (925) 708-8000
 rrubsamen@flowpharma.com
Business Contact
 Reid Rubsamen
Phone: (925) 708-8000
Email: rrubsamen@flowpharma.com
Research Institution
 University of Texas Medical Branch, Galveston National Laboratory
 Reid Rubsamen Reid Rubsamen
 
301 University Blvd.
Galveston, TX 77555
United States

 (925) 708-8000
 Nonprofit college or university
Abstract

Through this STTR contract, we propose to evaluate the efficacy of our vaccine, FlowVax Marburg, in nonhuman primates (NHPs). This will be achieved through four Tasks. In Task 1, we will manufacture the vaccine in a quantity sufficient for the animal studies. In Task 2, we will perform MHC genotyping on a representative population of NHPs and, based on results, select a set of MHC-matched NHPs for ensuing dose escalation and challenge studies. In Task 3, we will perform a dose escalation study in NHPs via direct lymph node immunization followed by aerosol challenge to a lethal dose of Marburg virus in order to assess efficacy. Finally, in Task 4, we will perform a dose escalation study in NHPs via intranasal immunization followed by aerosol challenge to a lethal dose of MARV in order to assess vaccine efficacy through this alternative mode of administration. This will allow us to compare the efficacy of FlowVax Marburg delivered by direct lymph node injection (Task 3) to intranasal delivery (representing a more practical method of vaccine delivery in humans).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government